Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
AssigneeIronwood Pharmaceuticals, Inc.
InventorsMark G. Currie, Daniel P. Zimmer
Life of this patent
Estimating the term…
Abstract
Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more sGC modulators alone or in combination with one or more lipid altering agents and/or PDE inhibitors.
Claims31
A method for preventing or treating lipid metabolism disorder, the method comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more soluble guanylate cyclase modulators.
5-10. (canceled)
(canceled)
21-39. (canceled)
41-49. (canceled)
A composition comprising a therapeutically effective amount of at least one soluble guanylate cyclase modulator and at least one lipid altering agent.
52-82. (canceled)
85-87. (canceled)
A composition comprising a therapeutically effective amount of at least one soluble guanylate cyclase modulator and at least one phosphodiesterase inhibitor.
90-106. (canceled)
108-110. (canceled)
Dependencies are inferred from the claim text.